July 2007
Worldwide Biotech;Jul2007, Vol. 19 Issue 7, p7
Trade Publication
The article focuses on the two-year research partnership forged by S*BIO Pte Ltd. with the National University Hospital-National University of Singapore Tissue Repository (NUH-NUS TR). The partnership is aimed at conducting biomarker research and at evaluating the responsiveness of tumors to the proprietary anti-cancer compounds of S*BIO. Information on the NUH-NUS TR is outlined.


Related Articles

  • Singapore's S*BIO Adds $26M for Phase II Studies in Cancer. Hollingsworth, Catherine // BioWorld Today;10/21/2008, Vol. 19 Issue 205, p1 

    The article reports that S*BIO Pte. Ltd. has raised $26 million to fund phase II trials for the SB939 and SB1518 cancer drugs in 2008. The financing was led by Bio*One Capital, a member of the Singapore Economic Development Authority and Aravis Venture. In a statement, chief executive Jan Anders...

  • Correction.  // BioWorld Today;4/6/2007, Vol. 18 Issue 67, p2 

    A correction to the misidentification of the location of the headquarters of the company S*BIO Pte. Ltd. that was published in the April 4, 2007 issue is presented.

  • S*BIO Adds $26M for Phase II Cancer Studies.  // Bioworld Week;10/27/2008, Vol. 16 Issue 43, p3 

    The article reports on the $26 million funds raised by S☆BIO Pte. Ltd. in 2008. The company raised $26 million in a Series B financing round, which will be used mainly to move its lead compound for cancer, SB939 and SB1518, into Phase II trials. SB939, currently in Phase I testing in both...

  • S*BIO INITIATES CLINICAL TRIAL OF NOVEL ANTI-CANCER DRUG.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p1 

    The article reports that the clinical trial of the novel anti-cancer drug was initiated by the S*BIO Pte Ltd. in Singapore. The SB939 is a histone deacetylase (HDAC) inhibitor which is a targeted anti-cancer therapeutics. The SB939 Phase I trial was conducted to determine its pharmacokinetic and...

  • CLINIC ROUNDUP.  // BioWorld Today;9/19/2008, Vol. 19 Issue 183, p7 

    This section offers news briefs on the pharmaceutical industry. Avigen Inc. has completed the double-blind portion of its Phase IIb trial for AV650 used in the treatment of spasticity linked to multiple sclerosis. Positive results were reported by Incyte Corp. from Phase IIa trials of topical...

  • Tragara Pays $112M to Develop S*BIO Compound.  // Bioworld Week;1/26/2009, Vol. 17 Issue 4, p3 

    The article reports on the $112 million deal between pharmaceutical companies S*BIO Pte. Ltd. and Tragara Pharmaceuticals Inc. in January 2009. The agreement signifies their collaborative effort in developing potential treatment for blood cancer and solid tumors. The project will initially focus...

  • European Haematology Association.  // BioWorld Today;6/15/2010, Vol. 21 Issue 114, p4 

    The article reports on the Phase I/II dose escalation trial of S*BIO Pte. Ltd.'s oral JAK2 inhibitor SB1518 which drew positive safety, tolerability and pharmacokinetic/pharmacodynamic findings.

  • Pacritinib Reduces Splenomegaly in Myelofibrosis Patients.  // Drug Discovery & Development;Jan2012, Vol. 15 Issue 1, p26 

    The article discusses the Phase 2 study of S*BIO Pte. Ltd. on its JAK2 inhibitor pacritinib (SB1518) which indicates that pacritinib significantly reduces splenomegaly in patients with myelofibrosis.

  • Use of Targeted Liposome-based Chemotherapeutics to Treat Breast Cancer. Khan, David R.; Webb, Maggie N.; Cadotte, Thomas H.; Gavette, Madison N. // Breast Cancer: Basic & Clinical Research;2015 S2, Issue 9, p1 

    The use of nanocarriers such as liposomes to deliver anticancer drugs to tumors can significantly enhance the therapeutic index of otherwise unencapsulated cytotoxic agents. This is in part because of the fact that the phospholipid bilayer can protect healthy sensitive tissue from the damaging...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics